Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CYCC NASDAQ:PALI NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.33-8.1%$0.40$0.24▼$2.53$20.98M0.9791,629 shs492,189 shsCYCCCyclacel Pharmaceuticals$9.72-13.3%$9.94$3.08▼$597.60$15.40M0.075.39 million shs145,070 shsPALIPalisade Bio$1.01-1.0%$0.79$0.60▼$4.32$4.89M1.341.14 million shs192,191 shsRLMDRelmada Therapeutics$0.59-5.1%$0.66$0.24▼$3.98$20.66M0.66191,554 shs328,058 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-8.10%-6.99%-17.02%-40.86%-81.77%CYCCCyclacel Pharmaceuticals-13.29%-39.40%+161.40%-83.88%-97.59%PALIPalisade Bio-0.98%-12.93%+38.45%+27.46%-74.23%RLMDRelmada Therapeutics-5.14%-8.71%-1.78%+61.71%-83.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.0646 of 5 stars3.31.00.00.02.22.50.6CYCCCyclacel Pharmaceuticals0.2531 of 5 stars0.02.00.00.01.11.70.0PALIPalisade Bio2.7055 of 5 stars3.54.00.00.01.90.01.3RLMDRelmada Therapeutics4.4542 of 5 stars3.15.00.04.40.04.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,415.15% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/APALIPalisade Bio 3.00Buy$12.001,088.12% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00746.88% UpsideCurrent Analyst Ratings BreakdownLatest PALI, CYCC, BCAB, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M1.75N/AN/A$0.25 per share1.32CYCCCyclacel Pharmaceuticals$14K1,100.44N/AN/A($58.87) per share-0.17PALIPalisade Bio$250K19.39N/AN/A$2.71 per share0.37RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)PALIPalisade Bio-$14.44M-$6.80N/AN/AN/AN/A-178.96%-127.35%8/11/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/7/2025 (Estimated)Latest PALI, CYCC, BCAB, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BCABBioAtla-$0.29N/AN/AN/AN/AN/A8/11/2025Q2 2025PALIPalisade Bio-$0.48N/AN/AN/AN/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25N/AN/AN/AN/AN/A5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals$0.151.54%N/AN/A N/APALIPalisade BioN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35CYCCCyclacel PharmaceuticalsN/A5.605.60PALIPalisade BioN/A2.842.84RLMDRelmada TherapeuticsN/A5.295.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CYCCCyclacel Pharmaceuticals23.58%PALIPalisade Bio11.79%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CYCCCyclacel Pharmaceuticals51.20%PALIPalisade Bio3.28%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableCYCCCyclacel Pharmaceuticals141.59 million773,000OptionablePALIPalisade Bio104.80 million4.64 millionNot OptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionablePALI, CYCC, BCAB, and RLMD HeadlinesRecent News About These CompaniesRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025July 31 at 7:00 AM | globenewswire.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21, 2025 | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, CYCC, BCAB, and RLMD Company DescriptionsBioAtla NASDAQ:BCAB$0.33 -0.03 (-8.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.34 +0.01 (+2.73%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Cyclacel Pharmaceuticals NASDAQ:CYCC$9.72 -1.49 (-13.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.60 -0.12 (-1.23%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Palisade Bio NASDAQ:PALI$1.01 -0.01 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.99%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Relmada Therapeutics NASDAQ:RLMD$0.59 -0.03 (-5.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.61 +0.02 (+3.32%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
